Jakob Habib

2 months ago | onlinelibrary.wiley.com | Brendan P. Lovasik |Abraham J. Matar |Jakob Habib |David Faber

1 Introduction The presence of strong anti-donor antibodies represents a formidable barrier in solid organ transplantation. For patients on the waiting list, broad levels of sensitization considerably prolong waiting times, and preformed anti-donor antibodies increase the risk of antibody-mediated rejection (ABMR) after receipt of a transplant [1]. For patients with an existing graft, de novo antibody formation poses the risk of graft injury and potential graft loss.